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Abstract
Background: The liver X receptors (LXR) a and b regulate lipid and carbohydrate homeostasis and inflammation.
Lxrb
-/- mice are glucose intolerant and at the same time lean. We aimed to assess the associations between single
nucleotide polymorphisms (SNPs) in LXRb and risk of type 2 diabetes mellitus (T2DM), obesity and related traits in 3
separate cohort studies.
Methods: Twenty LXRb SNPs were identified by sequencing and genotyped in the HUNT2 adult nested case-
control study for T2DM (n = 835 cases/1986 controls). Five tag-SNPs (rs17373080, rs2695121, rs56151148, rs2303044
and rs3219281), covering 99.3% of the entire common genetic variability of the LXRb gene were identified and
genotyped in the French MONICA adult study (n = 2318) and the European adolescent HELENA cross-sectional
study (n = 1144). In silico and in vitro functionality studies were performed.
Results: We identified suggestive or significant associations between rs17373080 and the risk of (i) T2DM in HUNT2
(OR = 0.82, p = 0.03), (ii) obesity in MONICA (OR = 1.26, p = 0.05) and (iii) overweight/obesity in HELENA (OR =
1.59, p = 0.002). An intron 4 SNP (rs28514894, a perfect proxy for rs17373080) could potentially create binding sites
for hepatic nuclear factor 4 alpha (HNF4a) and nuclear factor 1 (NF1). The C allele of rs28514894 was associated
with ~1.25-fold higher human LXRb basal promoter activity in vitro. However, no differences between alleles in
terms of DNA binding and reporter gene transactivation by HNF4a or NF1 were observed.
Conclusions: Our results suggest that rs17373080 in LXRb is associated with T2DM and obesity, maybe via altered
LXRb expression.
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Liver X receptors (LXRs) are nuclear receptors involved
in control of carbohydrate and lipid homeoastasis as
well as inflammation [1-3]. The LXRs consist of two iso-
forms which share approximately 78% amino acid
sequence identity: LXRa, encoded by NR1H3 (11p11.2)
and LXRb encoded by NR1H2 (19q13.3). High expres-
sion of LXRa is restricted to metabolically active tissues,
whereas LXRb is ubiquitously expressed [4]. LXRb is
the only isoform expressed in pancreatic beta cells [5].
LXRs regulate gene expression by binding to specific
response elements in the target genes’ promoter regions
[6-8].
Study of mice lacking one LXR isoform or both has
shown important, specific functions of LXRb in meta-
bolic pathways disturbed in type 2 diabetes mellitus
(T2DM) and obesity [9,10]. Firstly, Lxrb
-/- mice exhibit
markedly lower glucose tolerance [11] with reduced
basal and glucose-stimulated insulin secretion than wild
type (wt) mice [5]. The stimulatory effect of LXR ago-
nists on insulin secretion seems to be mediated by regu-
lating both glucose and lipid metabolism in pancreatic
beta cells [5,12]. Chronic, increased activation of LXR
may contribute to the dysfunction of pancreatic beta
cells observed in T2DM [13]. Secondly, Lxrb
-/- mice
have less adipose tissue with lower triglyceride (TG)
levels but similar insulin sensitivity as wt mice [11,14].
The lack of LXRb appears to be responsible for the lean
phenotype in Lxra
-/-b
-/- mice [9].
Therefore, specific LXRb activation could potentially
dissociate the LXR agonists’ anti-atherosclerotic and
anti-diabetic effects from their hypertriglyceridaemic
effects and possibly serve as the basis of a treatment for
T2DM [10,15].
We made the hypothesis that the genetic variability of
LXRb could be associated with fat mass, glucose meta-
bolism and related phenotypes in humans. In the pre-
sent study, we identified single nucleotide
polymorphisms (SNPs) in the LXRb gene by sequencing
DNA from 96 individuals (86 patients with metabolic
dysfunctions in glucose and lipid homeostasis and 10
h e a l t h yc o n t r o l s ) .W et h e np erformed association stu-
dies to determine if the LXRb SNPs were associated
with T2DM (in one case-control study), obesity or
related phenotypes (in two - adult and adolescent -
population based-studies). Finally, the functionality of
one SNP was assessed in silico and in vitro.
Methods
The HUNT2 study
The Nord-Trøndelag Health Study 2 (HUNT2 Study)
has been described elsewhere http://www.ntnu.no/eng-
lish[16]. In brief, it was a large (n = 65,905), population-
based health survey carried out in Norway during 1995-
97. Data were obtained from non-fasting blood samples,
a clinical examination and questionnaires [17]. From
this large sample, 1040 diabetic subjects (942 individuals
with self-reported diabetes and 98 individuals with a
non-fasting serum glucose level >11.1 mmol/l) were ran-
domly selected excluding type 1 diabetic subjects (n =
171) as described [17]. The investigators also selected
2080 age- and gender- matched non-diabetic control
subjects with a serum glucose level ≤5.5 mmol/l. DNA
samples were available for 2821 subjects (835 T2DM
subjects and 1986 controls) [18]. Their characteristics
are described in Additional file 1: Table 1. The use of
data and DNA materials from these subjects for the pre-
sent study was approved by the Norwegian Regional
Committee for Medical Research Ethics (Southern
Region), the Norwegian Social Data Services and the
Norwegian Directorate for Health and Social Affairs.
The MONICA study
Participants were recruited as part of the WHO-MON-
ICA population survey conducted from 1995 to 1997 in
the Lille Urban Community (Lille, n = 1195) and the
Haute-Garonne county (Toulouse, n = 1182) in France.
Individuals aged 35-65 years were randomly selected
from electoral rolls (the WHO-MONICA Project proto-
col) [19]. The study protocol was approved by the
appropriate independent ethics committees for each
centre. After signing an informed consent form, partici-
pants filled out a standard questionnaire. The measure-
ment of anthropometric, clinical and biochemical
parameters has been described [20]. Fasting blood sam-
ples were drawn into a disodium EDTA tube. DNA
samples were available for 2318 individuals. Their char-
acteristics are described in Additional file 1: Table s1.
The HELENA study
Participants were recruited as part of the HELENA
cross-sectional study ("Healthy Lifestyle in Europe by
Nutrition in Adolescence-Cross Sectional Study”, http://
www.helenastudy.com) performed from 2006 to 2007 in
10 centres from 9 European countries as described [21].
The protocol was approved by the appropriate ethics
committee in each centre. Written informed consent
was obtained from each subject and their legal represen-
tatives. The sample included 3865 adolescents (14.8 ±
1.4 y) recruited through their schools which were ran-
domly selected [22]. The measurement of the anthropo-
metric parameters has been described elsewhere [23].
Overweight/obesity was defined as a BMI over the value
given by Cole et al. [24], corresponding to 25/30 kg/m
2
at the age of 18. One third of the classes were randomly
selected for fasting blood collection, resulting in a total
of 1144 subjects whose characteristics are described in
Additional file 1: Table s1. DNA extractions and the
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described [23].
Gene sequencing
Ten normolipidaemic controls and 86 patients with
metabolic syndrome according to the NCEP Expert
Panel 2002 definition [25] were recruited at Oslo Uni-
versity Hospital Rikshospitalet and Ulleval, Norway.
EDTA blood was collected from the 96 individuals, and
genomic DNA was extracted using the MagNaPure LC
instrument with DNA isolation kit I (Roche Applied
Science, IN, USA). In order to identify as many LXRb
variants as possible, the LXRb gene (all exons, exon-
intron junctions, 3126 bp 5’ of the ATG and 935 bp 3’
of the last exon; primer positions in Additional file 1:
Table s2) was sequenced in DNA from the 96 indivi-
duals, and the SNPs identified were confirmed as
described [26] (Table 1).
Genotyping
I nt h eH U N T 2S t u d y ,t h eS N P sw e r eg e n o t y p e do na
MASSARRAY system (Sequenom, San Diego, CA, USA)
as described elsewhere [26]. The genotyping success
rates (GSRs) were over 98% (except for rs77094157,
rs12972221 and rs55671147). In the HELENA study,
genotyping was performed on an Illumina system using
Table 1 SNPs detected by sequencing the LXRb gene
# rs number Position on
chromosome 19
Position
from ATG
Location Base
change
MAF in sequenced
individuals
(n = 96)
MAF in HUNT2
controls
(n = 1986)
MAF in
MONICA
(n = 2318)
MAF in
HELENA-CSS
(n = 1144)
1 rs79233036
a 55,569,984 -2692 5’ near
gene
C>T 0.005 (1
heterozygous
subject)
0- -
2 rs77094157
a 55,570,236 -2440 5’ near
gene
C>T 0.005 (1
heterozygous
subject)
NA - -
3 rs12972221 55,570,952 -1723 5’ near
gene
G>T 0.36 NA - -
4 rs17373080 55,571,336 -1339 5’ near
gene
C>G 0.37 0.35 0.31 0.32
5 rs56151148 55,571,364 -1311 5’ near
gene
C>T 0.05 0.08 0.09 0.08
6 rs55794952 55,571,487 -1188 5’ near
gene
G>T 0.005 (1
heterozygous
subject)
0.007 - -
7 rs2695121 55,572,553 -122 intron 2 C>T 0.44 0.44 0.43 0.40
8 rs55671147 55,572,866 +192 exon 4 G>A
(Glu36Glu)
0.03 NA - -
9 rs28514894 55,573,138 +464 intron 4 C>T 0.33 0.35 - -
10 rs2248949 55,573,981 +1306 intron 6 G>A 0.45 0.44 - -
11 rs41432149 55,573,984 +1309 intron 6 C>T 0.36 0.35 - -
12 rs77290536
a 55,574,080 +1405 exon 7 C>G
(Pro252Arg)
0.005 (1
heterozygous
subject)
0- -
13 rs78105260
a 55,574,374 +1700 intron 7 A>G 0.005 (1
heterozygous
subject)
0.007 - -
14 rs1405655 55,574,431 +1757 intron 7 C>T 0.36 0.35 - -
15 rs2303045 55,574,730 +2056 intron 7 C>G 0.35 0.35 - -
16 rs4802703 55,576,697 +4023 intron 8 A>C 0.40 0.32 - -
17 rs2303044 55,577,013 +4339 intron 8 A>G 0.10 0.07 0.08 0.08
18 rs1052677 55,577,993 +5319 3’ UTR C>G 0.16 0.09 - -
19 rs75967835
a 55,578,378 +5704 3’ near
gene
A>C 0.005 (1
heterozygous
subject)
0- -
20 rs3219281 55,578,899 +6225 3’ near
gene
C>T 0.15 0.09 0.09 0.10
Positions based on NM_007121 sequence. MAF: minor allele frequency. NA: not available.
The 5 SNPs selected for association studies are indicated in bold.
adiscovered by gene sequencing in the present study.
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the MONICA samples, genotyping was performed using
a PCR-RFLP method. Primers and conditions are avail-
able on request. The GSRs were over 98%. Two percent
of the samples were double genotyped and the concor-
dance rate was 100%. None of the genotype population
distributions deviated from the Hardy-Weinberg equili-
brium, except for rs2303044 in the MONICA study (p =
0.017). However, Hardy-Weinberg equilibrium was
respected in the subgroup of normal-weight subjects (n
= 1076, p = 0.14).
Vectors
The pGL3-LXRb vector was obtained by amplification of
the 1922 bp fragment (-201/+1721 bp in reference to
the transcription start site) containing part of the pro-
moter through to the end of intron 4 of the LXRb gene
in its two allelic forms (T and C) for rs28514894 (an
intermediate step was performed in a TA cloning
pCR®II vector (Invitrogen)). Primers were 5’-GGCCGCA
GGCTCAGAGAAGCG-3’ (forward) and 5’-CTGGGGT
GGGTAGGTAGAGGC-3’ (reverse). Insertion into the
pGL3-basic luciferase reporter vector (Promega, Madi-
son, WI) was checked by sequencing. The pCH-NF1A,
B, C and X expression vectors were a kind gift from Dr
R. Gronostajski (Buffalo, NY, USA). The pCMV6-XL4-
HNF4a expression vector was purchased from OriGene
Technologies, Inc. (Rockville, MD, USA) (TrueClone
SC123863).
In silico analyses
MatInspector version 7.0 [27] (Genomatix Software
GmbH, Munich Germany) was used to identify which
transcription factor binding sites were affected by the
SNPs, using the vertebrate matrix.
Cell lines and transient transfections
The human JEG3 choriocarcinoma and HepG2 hepatoma
cell lines (ATCC) were cultured according to the manufac-
turer’s recommendations. 70% confluent cells in 24-well
plates were transfected with 500 ng of pGL3 vector ± 250
ng of HNF4a or NF1 expression vectors with a FuGENE
HD (Roche Applied Science):DNA ratio of 5:1 for HepG2
cells and 4:1 for JEG3 cells. Luciferase activities were mea-
sured 40 hr after transfection using the Dual Luciferase
A s s a yk i t( P r o m e g a ,M a d i s o n ,W I ) .T h efirefly luciferase
activity of the pGL3 vectors was normalized against the
renilla luciferase activity shown by the co-transfected
pRL-CMV vector (Promega, Madison, WI, USA).
Electrophoretic Mobility Shift Assays (EMSAs)
JEG3 cells were transfected in 10 cm dishes with 4 μg
NF1 expression vector and 8 μl LipofectAMINE 2000
(Invitrogen). Nuclear extracts were isolated using
CelLytic NuCLEAR Extraction Kit (Sigma-Aldrich) with
the addition of extra EDTA-free complete proteinase
inhibitor cocktail (Roche Applied Science). The oligonu-
cleotides were: rs28514894 T allele 5’-TCCTCTGGCTC
TTTGCCTGGGGATC-3’, rs28514894 C allele 5’-
TCCTCTGGCTCTTTGCCCGGGGATC-3’ (bold letters
indicate the SNP), NF1 positive control 5’-GCGGCTCT
TGGCCCAAAGCCAGACCT-3’ and NF1 negative con-
trol 5’-TCCTACTTACACCCTAAGTTTTATC-3’ (heav-
ily mutated to hinder NF1 binding). The double-
stranded oligonucleotides were radiolabelled and the
probes were purified. This was followed by binding reac-
tions and then separation of the protein-DNA com-
plexes from the unbound probes, as described [28]. For
supershift assays, 1 μL of anti-haemagglutinin (HA)
mouse antibody (Roche Diagnostics GmbH) was pre-
incubated with nuclear extracts for 45 minutes at 4°C.
Statistical analyses
The linkage disequilibrium (LD) between SNPs was eval-
uated using Haploview [29] and Thesias [30] softwares.
All statistical analyses were performed with SAS statisti-
cal software (SAS Institute Inc., Cary, NC, USA). Odds
ratios were obtained by multivariate logistic regression
analyses. To see if the odds ratios were similar between
the MONICA studies, the Breslow-Day test of homoge-
neity of odds ratios was calculated. In order to obtain
normal data distributions, log-transformation was used
for TG and insulin levels in all samples and for glucose
levels in the MONICA sample and an exponential trans-
formation was applied to glucose levels in the HUNT2
study. Inter-group comparisons of quantitative variables
were made using a general linear model procedure.
Reported p values are nominal and were systematically
adjusted for confounding variables. The additive, domi-
nant (and recessive when possible) models were tested
but only the best model is actually presented. There was
no significant interaction with gender for any of the
SNPs in the 3 studies. The threshold for statistical signifi-
cance was set to p ≤ 0.01 (0.05/5 tested SNPs).
Results
Identification of LXRb SNPs and haplotype blocks
By sequencing the LXRb gene in 96 individuals 20 SNPs
were identified (Table 1). T2DM cases and control sub-
jects from the HUNT2 study were genotyped for these
SNPs. Three rare SNPs (rs79233036, rs77290536 and
rs75967835) could not be detected (all homozygous sub-
jects). The genotyping of three other SNPs (rs77094157,
rs12972221 and rs55671147) suffered from unspecific
amplification or low GSR. Rs12972221 was in complete
LD with rs17373080 (D’ =+ 1 ,r
2 = 1). Given that the
rs77094157 and rs55671147 SNPs had a low minor allele
frequency (MAF), they were not further investigated in the
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subsequently analysed. LD between these 12 SNPs was
evaluated in control subjects from the HUNT2 study
(Figure 1). Three blocks were detected (r
2 > 0.80). The
first included rs17373080, rs28514894, rs41432149,
rs1405655, rs2303045 and rs4802703. Rs17373080 was
chosen as a tag-SNP for this block. The second block was
composed of rs1052677 and rs3219281 (chosen as a tag-
SNP). The third block was composed of rs2248949 and
rs2695121 (chosen as a tag-SNP). Thus, the three tag-
SNPs (rs17373080, rs3219281 and rs2695121) and the two
SNPs (rs56151148 and rs2303044) showing little LD with
other SNPs were selected, covering 99.3% of the entire
common genetic variability of the LXRb gene.
Association between the LXRb SNPs and T2DM in HUNT2
We compared the genotype distributions of the 5 SNPs in
individuals with T2DM (n = 835) and controls (n =1 9 8 6 ) .
No significant distribution differences were found (Table
2). However, when considering a dominant model, there
w a ss u g g e s t i v ee v i d e n c ef or association between
rs17373080 and the risk of T2DM. Indeed, subjects carry-
ing the minor G allele had a lower risk of T2DM than CC
subjects did (OR [95% CI] = 0.82 [0.69-0.98], p = 0.03).
Association between the LXRb SNPs and obesity in
MONICA
Individuals from the MONICA Lille and Toulouse sam-
ples (total n = 2318) were genotyped for the 5 SNPs. ORs
for obesity in minor alleles carriers were homogenous in
the 2 samples (Breslow-Day tests). Genotype distribu-
tions of the 5 SNPs for obese (BMI≥30 kg/m
2, n =3 7 3 )
versus non-obese (BMI <30 kg/m
2, n = 1945) individuals
were compared (Table 3); there were no significant inter-
group differences. However, in a dominant model,
rs17373080 tended to be associated with the phenotype
in question (OR for obesity= 1.26 [1.00-1.59] (p = 0.05)
for G allele carriers, relative to CC individuals). Haplo-
type analyses performed with THESIAS did not provide
additional information (data not shown).
Association between the LXRb SNPs and obesity/
overweight in HELENA
Adolescents from the HELENA study (n = 1144) were
genotyped for the 5 SNPs. To gain statistical power,
obese (n = 70) and overweight (n = 195) adolescents
were pooled. The genotype distributions of the 5 LXRb
SNPs between obese/overweight (n = 265) and normal-
weight (n = 879) adolescents were compared (Table 4).
As for the MONICA study, the G allele of rs17373080
was associated with a significant higher risk of over-
weight/obesity (OR = 1.59 [1.19-2.13], p =0 . 0 0 2 ) .M o r e -
over, individuals carrying either the T allele of rs2303044
or the T allele of rs3219281 also had a significant higher
risk of obesity (OR = 1.84 [1.27-2.66], p = 0.001, and 1.78
[1.25-2.52], p = 0.001, respectively), compared with
homozygous CC individuals. Haplotype analyses did not
provide additional information (data not shown).
Association between the LXRb SNPs and obesity- or
T2DM-related quantitative phenotypes in HUNT2,
MONICA and HELENA
In the three cohorts, we examined associations between
the 5 LXRb SNPs and the following obesity-/T2DM-
related quantitative phenotypes: BMI, waist circumference,
waist-to-hip ratio and plasma glucose and lipid levels.
In control individuals from the HUNT2 study, the G
allele of rs17373080 tended to be associated with lower
plasma glucose levels (4.96 ± 0.43 in G allele bearers
versus 4.99 ± 0.43 mmol/l in CC subjects, p =0 . 0 3 ) .
Rs56151148 T allele bearers tended to have lower
plasma TG levels (1.62 ± 0.91 versus 1.69 ± 0.92 mmol/
l, p = 0.03) compared with CC subjects (Additional file
1: Table s3).
In the MONICA study, there was suggestive evidence
for an association between the GG genotype of
rs17373080 with a higher waist-to-hip ratio (0.893 ±
0.095 in GG subjects versus 0.884 ± 0.092 in C allele
bearers, p = 0.03) (Additional file 1: Table s4). More-
over, rs3219281 T allele carriers had significantly higher
plasma TG levels (1.40 ± 1.10 versus 1.28 ± 0.94 mmol/
l, p = 0.01) than CC subjects.
In the HELENA study, rs17373080 G allele bearers
had higher fasting insulin levels (10.51 ± 6.66 versus
9.24 ± 4.84 μU/ml, p = 0.04) and higher HOMA-IR
index (2.36 ± 1.52 versus 2.07 ± 1.22, p = 0.02) than CC
subjects (Additional file 1: Table s5). Subjects carrying
the rs2695121 T allele had lower fasting insulin levels
Figure 1 Linkage disequilibrium map of the 12 LXRb SNPs
(MAF≥0.05) genotyped in the HUNT2 study. The linkage
disequilibrium was analysed using genotypes from control
individuals in the HUNT2 study. D’ and r
2 values were calculated
using Haploview software. D’ values ranged between 0.88 and 1
and are represented by a red gradation. r
2 values (in %) are given
within the diamonds.
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Page 5 of 11(9.44 ± 5.12 versus 10.85 ± 6.98 μU/ml, p =0 . 0 0 8 ) ,
lower HOMA-IR index (2.10 ± 1.18 versus 2.45 ± 1.71,
p =0 . 0 0 2 )a n dt e n d e dt oh a v eal o w e rH O M A - Bc e l l
index (136.7 ± 127.3 versus 153.1 ± 110.9%, p =0 . 0 3 )
compared with CC subjects. The T allele of rs2303044
was associated with a higher BMI (22.1 ± 4.3 in T allele
carriers versus 21.2 ± 3.6 kg/m
2 in CC subjects, p =
0.006). Lastly, rs3219281 T allele carriers had higher
BMI (21.9 ± 4.2 versus 21.2 ± 3.6 kg/m
2, p =0 . 0 0 9 )a n d
a higher waist circumference (73.4 ± 10.7 versus 72.0 ±
9.0 cm, p = 0.03) than CC subjects.
Meta-analysis on fat mass indices
We performed a meta-analysis for the 5 SNPs regarding
BMI or waist-to-hip ratio. When combining the two
adult HUNT2 and MONICA studies (n = 4304), the T
allele of rs2303044 was marginally associated with
higher waist-to-hip ratio (effect size: +0.0055 ± 0.0028, p
= 0.05 (heterogeneity p = 0.86)). Similar association was
detected for the T allele of rs3219281 and waist-to-hip
ratio (effect size: +0.0051 ± 0.0024, p =0 . 0 3( h e t e r o g e -
neity p = 0.55)). When combining the three HUNT2,
MONICA and HELENA studies (n = 5448), the T allele
of rs2303044 was significantly associated with higher
BMI (effect size: +0.41 ± 0.19 kg/m
2, p = 0.0096 (hetero-
geneity p = 0.39)).
In silico and in vitro functional studies of rs28514894
In silico analyses with MatInspector software were per-
formed to determine which relevant transcription factor
(TF) binding sites were potentially affected by the SNPs.
All SNPs in strong LD (r
2 = 0.80) with the rs17373080
SNP (i.e. rs28514894, rs41432149, rs1405655, rs2303045
and rs4802703) were tested. The C allele of rs28514894
(located in intron 4 (intron 2 after the translation initia-
tion site)), a perfect proxy for the G allele of 17373080
(r
2 = 0.99), could theoretically create a binding site for
hepatic nuclear factor 4 alpha (HNF4a) (core similarity
= 1.0, matrix similarity = 0.87) or nuclear factor 1
(NF1A, B, C and X) (core similarity = 0.76, matrix
Table 2 Genotype distribution for the 5 LXRb; SNPs in individuals with and without T2DM from the HUNT2 study and
ORs [95% CI] of T2DM
Genotype Controls (n = 1986) T2DM (n = 835) Crude p Adjusted OR [95% CI] Adjusted p
n Frequency n Frequency
rs17373080 CC 815 0.41 381 0.46
CG 934 0.47 367 0.44 0.08 0.82 [0.69-0.98] 0.03
GG 236 0.12 87 0.10
Total 1985 835
rs56151148 CC 1655 0.84 684 0.82
CT 303 0.15 141 0.17 0.23
a 1.15 [0.92-1.45] 0.22
TT 12 0.01 9 0.01
Total 1970 834
rs2695121 CC 629 0.32 262 0.31
CT 970 0.49 401 0.48 0.79 1.02 [0.85-1.23] 0.80
TT 382 0.19 170 0.20
Total 1981 833
rs2303044 CC 1726 0.87 733 0.88
CT 242 0.12 96 0.12 0.43
a 0.84 [0.65-1.09] 0.20
TT 12 0.01 2 0.00
Total 1980 831
rs3219281 CC 1624 0.83 696 0.84
CT 323 0.16 128 0.15 0.27
a 0.87 [0.69-1.10] 0.25
TT 21 0.01 4 0.00
Total 1968 828
aFisher exact test.
ORs and p values were adjusted for age, gender and BMI.
A dominant model was used to calculate the odds ratios.
Significant p values are indicated in bold.
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rs28514894 could modulate the LXRb transcription
level.
To test the functionality of the theoretical NF1 bind-
ing sites, we conducted electrophoretic mobility shift
assays (EMSAs) with nuclear extracts from JEG3 cells
(known not to express NF1) transfected with NF1
expression vectors. Our results showed that the NF1
isoforms could bind similarly to the binding site, regard-
less of the allele (T or C) (Figure 2). Protein binding to
the C allele probe was prevented by adding a 10-fold
excess of unlabelled T allele probe and vice versa.T h e
specificity of this binding was confirmed, with complete
supershifts when adding the anti-HA tag antibody
(Figure 2). Nuclear extracts prepared from cells trans-
fected with empty vectors did not bind to any of the
probes. Similar experiments were conducted with
HNF4a with the same results (data not shown).
The impact of rs28514894 on LXRb promoter activity
was also evaluated. We cloned a 1922-bp fragment con-
taining the transcription start site up until the end of
i n t r o n4o ft h eLXRb gene in its two allelic forms (T
and C) into the pGL3-basic luciferase reporter vector
and thus created the pGL3-LXRb vector. This gene por-
tion was transcriptionally active in both cell lines (~20
f o l da n d~ 3 0 0f o l dc o m p a r e dt ot h ee m p t yp G L 3b a s i c
vector in HepG2 and JEG3 cells, respectively) (Figures
3 Aa n d3 B ) .I nt h eb a s a ls t a t e ,t h eLXRb fragment dis-
played ~1.25-fold higher activity (p < 0.05) when carry-
ing the C allele than when carrying the T allele in
HepG2 and JEG3 cells. Since rs28514894 is located in a
putative binding site for HNF4a and NF1s, the pGL3-
LXRb vector was co-transfected with HNF4a or NF1
expression vectors. In HepG2 cells, HNF4a increased
LXRb’s activity to a similar extent for the two allelic
forms (~1.6 fold for both) (Figure 3A). NF1s repressed
LXRb activity by approximately 60% and to a similar
extent for the two allelic forms (Figure 3A). Similar
results were obtained using the four different NF1s
(data not shown) and when using JEG3 cells, except a
repressor effect of HNF4a on LXRb in the latter case
(Figure 3B).
Table 3 Genotype distribution for the 5 LXRb; SNPs in obese and non obese individuals from the MONICA study and
ORs [95% CI] of obesity
Genotype Non obese (n = 1945) Obese (n = 373) Crude p Adjusted OR [95% CI] Adjusted p
n Frequency n Frequency
rs17373080 CC 937 0.48 157 0.43
CG 804 0.42 166 0.45 0.13 1.26 [1.00-1.59] 0.05
GG 191 0.10 43 0.12
Total 1932 366
rs56151148 CC 1595 0.83 314 0.85
CT 325 0.17 53 0.14 0.46
a 0.78 [0.57-1.08] 0.13
TT 11 0.01 1 0.00
Total 1931 368
rs2695121 CC 616 0.32 128 0.35
CT 947 0.49 182 0.49 0.30 0.90 [0.71-1.14] 0.39
TT 370 0.19 59 0.16
Total 1933 369
rs2303044 CC 1658 0.85 308 0.83
CT 262 0.14 60 0.16 0.41
a 1.23 [0.91-1.67] 0.18
TT 20 0.01 3 0.01
Total 1940 371
rs3219281 CC 1571 0.83 305 0.82
CT 310 0.16 61 0.16 0.77
a 1.03 [0.76-1.39] 0.85
TT 19 0.01 5 0.01
Total 1900 371
aFisher exact test. ORs and p values were adjusted for age, gender, centre, smoking habit, alcohol consumption and physical activity level. A dominant model
was used to calculate the odds ratios. Significant p values are indicated in bold.
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In the present work, we characterized the impact of the
entire common genetic variability of the LXRb gene and
searched for associations between 5 tagSNPs and various
metabolic phenotypes in 3 independent samples. We
report a suggestive association between the rs17373080
minor G allele (representing a 5.7 kbp haplotype block)
in LXRb and an approximately 20% lower risk of T2DM
in the HUNT2 study. The MONICA study containing
only 209 individuals with type 2 diabetes and the
HELENA study (adolescents) none, these population
samples are not suitable for replication of the associa-
tion between SNPs and diabetes risk found in HUNT2.
However, this result is in line with recent work by Dahl-
man et al., who showed that this allele was associated
with a 30% lower risk of T2DM in a study comprising
988 cases and 941 controls [31]. This protective effect
can be explained by the lower plasma glucose levels
observed in the non-diabetic subjects of the HUNT2
study carrying the G allele. Moreover, we found two
LXRb SNPs (rs17373080 and rs2695121) associated with
insulin levels and HOMA indexes in adolescents. These
associations could reflect LXRb’s role in insulin secre-
tion, since it has been shown that LXRb activation in
pancreatic beta cells increases insulin expression and
secretion via the SREBP-1 regulated pathway [5,12].
We also showed that the G allele of rs17373080 was
associated with higher risk of obesity or overweight in
the MONICA and the HELENA studies, respectively. In
line with our results, Dahlman et al. reported a marginal
association (p = 0.06) between rs17373080 and the risk
of obesity in a study of 559 obese and 438 non-obese
individuals [32]. However, they detected no association
between rs17373080 and BMI as a continuous trait in
1721 adults [31]. We confirmed this absence of associa-
tion in a larger sample (n = 5448). Only rs2303044 was
significantly associated with BMI when combining the 2
adult and the adolescent studies. The presence of many
confounding factors and compensation mechanisms may
hide the impact of LXRb on fat mass.
The opposing effects of the rs17373080 G allele on
obesity (deleterious) and T2DM (protective) may appear
to be contradictory. However, LXRb seems to play
opposing roles in fat metabolism and glucose
Table 4 Genotype distribution for the 5 LXRb; SNPs in overweight or obese and normal weight individuals from the
HELENA study and ORs [95% CI] of overweight/obesity
Genotype Normal weight (n = 879) Overweight/obese (n = 265) Crude p Adjusted OR [95% CI] Adjusted p
n Frequency n Frequency
rs17373080 CC 427 0.49 102 0.39
CG 366 0.42 125 0.48 0.01 1.59 [1.19-2.13] 0.002
GG 85 0.10 36 0.14
Total 878 263
rs56151148 CC 728 0.83 233 0.88
CT 142 0.16 31 0.12 0.13
a 0.72 [0.47-1.11] 0.14
TT 9 0.01 1 0.00
Total 879 265
rs2695121 CC 301 0.34 106 0.40
CT 430 0.49 123 0.47 0.15 0.76 [0.57-1.02] 0.071
TT 148 0.17 35 0.13
Total 879 264
rs2303044 CC 761 0.87 207 0.78
CT 111 0.13 53 0.20 0.003
a 1.84 [1.27-2.66] 0.001
TT 5 0.01 4 0.02
Total 877 264
rs3219281 CC 732 0.83 200 0.75
CT 138 0.16 59 0.22 0.01
a 1.78 [1.25-2.52] 0.001
TT 9 0.01 6 0.02
Total 879 265
aFisher exact test. ORs and p values were adjusted for age, gender and centre. A dominant model was used to calculate the odds ratios. Significant p values are
indicated in bold.
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Page 8 of 11homeostasis. Lxrb
-/- mice display lower amounts of adi-
pose tissue on one hand and glucose intolerance (due to
impaired glucose-induced insulin secretion) on the other
[11]. Furthermore, the effects of the rs17373080 G allele
on obesity and T2DM seem to be the opposite of what
would be expected from the Lxrb
-/- mouse phenotype
[11]. However, this may reflect species differences, as
discussed by Dahlman et al.[ 3 1 ] .A l s o ,t h i sm a yr e v e a l
differences between a complete gene knock-out and
subtle changes like SNPs. The SNPs may induce the
recruitment of different co-factors that modify the effect
of LXRb on target genes. For example, if the disease-
associated allele creates a binding site for a transactiva-
tor, the disease association would be opposite to the
effect observed in the Lxrb
-/- mice. Furthermore, epige-
netic changes may be involved. Lastly, the fact that
LXRb is expressed in several organs and tissues with dif-
ferent regulatory mechanisms adds to the complexity of
the association. Indeed, as shown in our transient
transfection experiments, HNF4a activated LXRb in
HepG2 but repressed it in JEG3 cells. The full mechan-
istic and physiological relevance of the statistical asso-
ciations found in this and other previous studies should
be elucidated in other cell lines expressing the LXRb
gene in its various allelic forms.
To the best of our knowledge, no LXRb SNPs have
been significantly associated with obesity or T2DM in
genome-wide association studies (GWAS). However,
due to the very low p-value threshold required in
GWAS (<10
-8), nominal associations with LXRb SNPs
gene (albeit weak) may have gone unreported. The
Figure 2 EMSA experiments showed no difference in TF
binding between the rs28514894 SNP alleles, as exemplified
by NF1C binding. EMSA of nuclear extracts (2 μg) isolated from
JEG3 cells transfected with the NF1C expression vector revealed a
strong specific complex with the LXRb oligonucleotides
encompassing the rs28514894 SNP with both alleles (T or C). The
competition experiments were performed using a 10-fold excess of
unlabeled oligonucleotides (indicated by *). The upper arrow
indicates the supershift with anti-HA-mouse antibody binding to the
NF1C protein-oligonucleotide complex and the lower arrow
indicates the NF1C protein-oligonucleotide complexes.
Figure 3 Functional analyses of the rs28514894 SNP in
luciferase reporter gene transfections in HepG2 (A) and JEG3
(B) cells. HepG2 and JEG3 cells were transiently co-transfected with
either the empty basic-pGL3 (O) or the pGL3-LXRb*T allele or the
pGL3-LXRb*C allele vector with or without an HNF4a or NF1s
expression vector. Activity was expressed as fold activity compared
with the pGL3-LXRb*T vector and the empty basic-pGL3 vector.
White and black bars represent activities obtained without or with
HNF4a or NF1s, respectively. Each bar represents the means ± SEM
of at least 3 independent experiments. Firefly luciferase activities
were normalized against renilla luciferase activities. Data were
compared using the Kruskal-Wallis non-parametric test. *p < 0.05, **
p < 0.01.
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Page 9 of 11associations in our present study were probably overesti-
mated, since the number of subjects was lower than in
GWAS. Nevertheless, GWAS do not cover the entire
genetic variability of each gene. Thus, a candidate gene
approach, as in the present study, may help detect asso-
ciations between SNPs and disorders.
While performing the present study, Dahlman et al.
[31] found a potential NF1 binding site overlapping
rs17373080 using the transcription element search sys-
tem and showed that NF1 could bind and regulate the
expression of the LXRb gene, whatever the allele. In
our study, a MatInspector analysis revealed that the
minor C allele of rs28514894 (in perfect LD with the
minor G allele of rs17373080) could create binding
sites for either HNF4a or NF1. We showed that the C
allele of rs28514894 was associated with higher LXRb
basal promoter activity, which suggested that this allele
was associated with higher LXRb mRNA levels. How-
ever, we did not observe major difference between the
two alleles in terms of DNA binding and transactiva-
tion by HNF4a or NF1s. Nevertheless, the inter-allele
differences in TF binding and transcriptional activity
may be too small to be detected by these methods but
can still make a difference in the whole organism over
the years - especially if (as would be expected) there
are tissue-specific effects.
Conclusions
In conclusion, our results suggest associations between
an LXRb block tagged by rs17373080 and the risks of
T2DM and obesity in adults, and the risk of overweight
in adolescents, confirming the recent studies by Dahl-
man et al. [31,32]. These findings however must be
interpreted with caution and replication in other large
population samples and performing meta-analyses are
necessary before a link between LXRb gene variability
and body weight metabolism can definitely be estab-
lished. Moreover, understanding the molecular mechan-
isms behind the LXRb SNP-disorder association will
require further experimentation.
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